Surgery – Means for introducing or removing material from body for... – Treating material introduced into or removed from body...
Reexamination Certificate
1999-12-27
2001-09-04
Nguyen, Anhtuan T. (Department: 3763)
Surgery
Means for introducing or removing material from body for...
Treating material introduced into or removed from body...
C604S288040, C604S153000, C128SDIG001
Reexamination Certificate
active
06283949
ABSTRACT:
BACKGROUND
1. Field of the Invention
This invention relates to drug delivery devices and more specifically to implantable devices for delivering drugs.
2. Description of Related Art
Localized drug delivery has become increasingly important in applications such as tissue engineering, growth regulation, pain control, and therapeutic approaches to localized disease conditions including tumors, local nervous system conditions, and local vascular system conditions. The action of many drugs is greatly enhanced by, or in some cases requires, long-term local delivery of those drugs into the patient's body.
One method of localized drug delivery is injection of the drug at a local site at which the drug acts. Localized drug delivery may be combined with a slow release drug formulation. Disadvantages of localized drug injection include the difficulty of stabilizing the drug over the total release period and adequately controlling the concentration profile of the drug over time at the site of action during delivery.
Another method for localized drug delivery includes inserting a catheter to direct the drug to the desired body site, and using a pump to impel a drug through the catheter. An externally worn pump is conventionally used with an internally implanted catheter. However, the site of entry into the patient's body is prone to infection. In addition, the externally worn pump is bulky and inconvenient.
Implantable drug delivery devices, implantable pumps, for example, have been developed to address the disadvantages of techniques that use external pump and catheter systems. Implantable drug delivery pumps often include a reservoir for storing the drug, an injection port to enable injection of fresh drug preparations at regular intervals into the reservoir, and optionally a catheter for delivering the drug to the desired site. Application of fresh drug preparations avoids a problem of long term stabilization. One disadvantage of implantable drug delivery devices is an inherent difficulty in controlling the dosage and delivery rates from the reservoir through the catheter. A further problem is that many of the applications for implantable drug delivery utilize drugs that are not stable at body temperature for extended periods.
An implantable device known as the Duros implant, which is manufactured and sold by Alza Corporation, Mountain View, Calif., provides drug treatment by osmotically delivering the drug preparation into the patient. Osmotic delivery uses neither mechanical or electronic assistance so that the Duros implant device can be made very small, about the size of a few matchsticks. However, the Duros implant does not permit an easily adjustable delivery rate, cannot be refilled, and requires surgical implantation. In addition, the Duros implant has only a very small reservoir for storing the drug preparation.
The limited capacity reservoir may not be a significant problem for short-term delivery of drugs, but many patients are unwilling to undergo surgical implantation for only a short-term benefit. To use the limited capacity reservoir for long-term drug delivery, a concentrated, potent drug preparation must be delivered in small dosages over an extended delivery period, resulting in problems of long-term drug instability and low precision in dosage control.
Another type of implantable drug delivery device is an infusion pump, such as a SynchroMed Infusion System which is manufactured and sold by Medtronic, Inc., Minneapolis. The device includes a catheter and a pump section. The pump section further includes a collapsible reservoir and a fill port for refilling the reservoir with fresh drug preparation. SynchroMed automatically delivers a controlled amount of medication through the catheter using an electronically driven pump. The dosage, rate, and timing are programmed into electronics contained within the pump section from an external programming device. The external programmer transmits programming information using radio waves.
SynchroMed solves some long-term delivery and dosage accuracy problems of other devices, but the pump section is large and bulky, measuring approximately 8.5 cm in diameter and 2.5 cm in height, and weighing about 205 g. The size of the SynchroMed limits the flexibility of doctors in implanting the device. Because of the large size and awkward hockey-puck shape, the SynchroMed device must typically be implanted in the abdominal cavity of a patient, and an extended catheter is passed through the patient's body to deliver the drug to the desired site of administration. In addition to problems with size and placement, the SynchroMed device is burdened by complex electronics for both programming and pumping functionality.
SUMMARY
In accordance with various aspects of the invention, an implantable drug delivery device includes a dispensing chamber having an upper surface, the dispensing chamber comprising a dispensing passage having an intake end and an outlet end, and an actuator for applying a compressive force on the dispensing passage moving in a direction from the intake end towards the outlet end. A reservoir housing is provided adjacent the upper surface of the dispensing chamber, and a reservoir in fluid communication with the intake end of the dispensing passage is provided in the reservoir housing. One-way intake valves at the intake and outlet ends of the dispensing passage ensure proper one-way flow of the drug preparation through the device.
In one aspect, the dispensing passage is a flexible tube along an interior portion of a dispensing chamber. An arm inside the dispensing chamber imposes a moving compressive force on the dispensing passage, thereby urging the drug preparation out of the outlet end and drawing additional drug preparation from the reservoir into the dispensing passage. Additional drug preparation can be injected into the reservoir through a septum on the device's housing.
In accordance with another aspect, a method for operating an implantable drug delivery device includes providing a dispensing chamber having an upper surface, an interior surface, and an outer circumferential surface, providing a dispensing passage along an interior surface of the dispensing chamber, and providing a reservoir filled with a fluid and in fluid communication with an intake end of the dispensing passage. The reservoir is housed in a reservoir housing adjacent to the upper surface of the dispensing chamber and having an outer circumferential surface concentric with the outer circumferential surface of the dispensing chamber. A compressive force is applied on the dispensing passage, and the compressive force is moved in a direction from the intake end towards an outlet end, thereby urging fluid contained between the compressive force and the outlet end out of the outlet end, and drawing fluid from the reservoir into the dispensing passage through the intake end.
REFERENCES:
patent: 4013074 (1977-03-01), Siposs
patent: 4210138 (1980-07-01), Jess et al.
patent: 4692147 (1987-09-01), Duggan
patent: 4931050 (1990-06-01), Idriss
patent: 5061242 (1991-10-01), Sampson
patent: 5207666 (1993-05-01), Idriss et al.
patent: 5443459 (1995-08-01), Wong et al.
patent: 5498255 (1996-03-01), Wong
patent: 5531736 (1996-07-01), Wong et al.
patent: 5752930 (1998-05-01), Rise et al.
patent: 5820589 (1998-10-01), Torgerson et al.
patent: 5836935 (1998-11-01), Ashton et al.
patent: 5843069 (1998-12-01), Butler et al.
patent: 5976109 (1999-11-01), Heruth
“There Is Only One Port-A-Cath®. . . ”, Port-A-Cath® Implantable Access Systems, SIMS Deltec, Inc. (1996).
“The Power of Two Materials in One Portal”, Port-A-Cath® II Implantable Access Systems, SIMS Deltec, Inc. (1996).
“Phase I/II Clinical Study Results of Duros™ Leuprolide Implant for Prostate Cancer Treatment Announced at AUA Meeting”, downloaded Dec. 20, 1999 from <http:www.alza.com/pr/PR374.htm> (Initial publication date listed as Jun. 4, 1998).
“Intraspinal Drug Delivery Pumps”, downloaded Dec. 20, 1999 from <http://www.asri.edu
euro/brochure/pain6.htm>, Allegheny-Singer
Advanced Cardiovascular Systems Inc.
Kang Peter H.
Nguyen Anhtuan T.
Skjerven Morrill & MacPherson
LandOfFree
Refillable implantable drug delivery pump does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Refillable implantable drug delivery pump, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Refillable implantable drug delivery pump will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2545223